复方福尔可定联合头孢克洛对急性呼吸道感染患儿疗效及机体炎性反应的影响  

The Effect of Compound Pholcodine Combined with Cefaclor on the Efficacy and Inflammatory Response of Children with Acute Respiratory Infections

作　　者：张美红 庄宇 王璐 ZHANG Meihong;ZHUANG Yu;WANG Lu(Outpatient Department of Children's Specialized Branch,Fuzhou First General Hospital,Fuzhou 350001,China)

机构地区：[1]福州市第一总医院儿童专科院区门诊,福州350001

出　　处：《中国医药指南》2024年第33期96-99,共4页Guide of China Medicine

摘　　要：目的探讨急性呼吸道感染患儿使用复方福尔可定联合头孢克洛的临床疗效与对机体炎性反应的影响。方法纳入2022年6月至2024年6月福州市第一总医院儿童专科院区门诊收治的急性呼吸道感染患儿150例,按照治疗方式的不同分为对照组(接受头孢克洛治疗)和观察组(接受复方福尔可定联合头孢克洛治疗),各75例。对比两组治疗前后炎症因子水平、免疫力水平、临床症状消失时间、治疗有效率和不良反应。结果治疗前,两组患儿白细胞介素-4(IL-4)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)和降钙素原(PCT)差异均无统计学意义(P>0.05),治疗后观察组指标水平均低于对照组(P<0.05)。治疗前两组免疫力CD8+细胞分数、CD4+细胞分数、CD8+细胞分数与CD4+细胞分数比值、免疫球蛋白E差异均无统计学意义(P>0.05),治疗后观察组CD4+、CD8+/CD4+与IgE均高于对照组,但CD8+低于对照组(P<0.05)。治疗后观察组咽痛、鼻塞、咳嗽、发热和咽部红肿临床症状消失时间均短于对照组,治疗总有效率高于对照组,发热、腹泻和皮疹的不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论对急性呼吸道感染患儿实施复方福尔可定联合头孢克洛用药能够显著改善患儿临床症状,降低炎症反应,提高机体免疫力,具有较好疗效。Objective To investigate the clinical efficacy and impact on inflammatory response of children with acute respiratory infections treated with compound pholcodine combined with cefaclor.Methods A total of 150 children with acute respiratory infections admitted to Outpatient Department of Children's Specialized Branch,Fuzhou First General Hospital in Fujian province from June 2022 to June 2024 were included.They were divided into a control group(receiving cefaclor treatment)and an observation group(receiving compound pholcodine combined with cefaclor treatment)according to different treatment methods,with 75 cases in each group.Compare the levels of inflammatory factors,immune system,disappearance time of clinical symptoms,treatment efficacy,and adverse reactions between two groups before and after treatment.Results Before treatment,there was no statistically significant difference in interleukin-4(IL-4),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP),and procalcitonin(PCT)between the two groups of children(P>0.05),after treatment,the levels of indicators in the observation group were lower than those in the control group(P<0.05).Before treatment,there was no statistically significant difference in the immune CD8+cell fraction,CD4+cell fraction,ratio of CD8+cell fraction to CD4+cell fraction,and immunoglobulin E between the two groups(P>0.05).After treatment,the observation group had higher CD4+,CD8+/CD4+,and IgE levels than the control group,but lower CD8+levels than the control group(P<0.05).After treatment,the observation group had shorter disappearance time of clinical symptoms such as sore throat,nasal congestion,cough,fever,and pharyngeal redness and swelling compared to the control group.The total effective rate of the observation group was higher than that of the control group,and the total incidence of adverse reactions such as fever,diarrhea,and rash was lower than that of the control group,with statistical significance(P<0.05).Conclusions The implementation of compound pholco

关 键 词：复方福尔可定 头孢克洛 急性呼吸道感染 炎症因子 

分 类 号：R725.6[医药卫生—儿科]